SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

This letter to the editor responds to comments on a recently published article on seroconversion rates after COVID-19 vaccination.

Detalles Bibliográficos
Autores principales: Guven, Deniz C, Sahin, Taha K, Akın, Serkan, Uckun, Fatih M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632303/
https://www.ncbi.nlm.nih.gov/pubmed/36005823
http://dx.doi.org/10.1093/oncolo/oyac173
_version_ 1784824005093490688
author Guven, Deniz C
Sahin, Taha K
Akın, Serkan
Uckun, Fatih M
author_facet Guven, Deniz C
Sahin, Taha K
Akın, Serkan
Uckun, Fatih M
author_sort Guven, Deniz C
collection PubMed
description This letter to the editor responds to comments on a recently published article on seroconversion rates after COVID-19 vaccination.
format Online
Article
Text
id pubmed-9632303
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96323032022-11-04 SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research Guven, Deniz C Sahin, Taha K Akın, Serkan Uckun, Fatih M Oncologist Letter to the Editor This letter to the editor responds to comments on a recently published article on seroconversion rates after COVID-19 vaccination. Oxford University Press 2022-08-25 /pmc/articles/PMC9632303/ /pubmed/36005823 http://dx.doi.org/10.1093/oncolo/oyac173 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Guven, Deniz C
Sahin, Taha K
Akın, Serkan
Uckun, Fatih M
SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
title SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
title_full SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
title_fullStr SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
title_full_unstemmed SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
title_short SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
title_sort sars-cov-2 vaccine efficacy in patients with hematologic malignancies: practical points for further research
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632303/
https://www.ncbi.nlm.nih.gov/pubmed/36005823
http://dx.doi.org/10.1093/oncolo/oyac173
work_keys_str_mv AT guvendenizc sarscov2vaccineefficacyinpatientswithhematologicmalignanciespracticalpointsforfurtherresearch
AT sahintahak sarscov2vaccineefficacyinpatientswithhematologicmalignanciespracticalpointsforfurtherresearch
AT akınserkan sarscov2vaccineefficacyinpatientswithhematologicmalignanciespracticalpointsforfurtherresearch
AT uckunfatihm sarscov2vaccineefficacyinpatientswithhematologicmalignanciespracticalpointsforfurtherresearch

Ejemplares similares